Member Info for Noise

Do they need shareholder approval to list on the Czech market? I would guess not

Hm, I went through this once a while back. They were worth 50p, bought out for 70p per share, one day the cash just appeared in my account and the shares had disappeared.

Antelope, I assume in that situation there may an EGM to approve major changes, but any payout would likely be similar to a dividend, certainly if you have standard ISA type accounts.

Indeed, by no means does it explicitly say phases 2-4 are happening, but the way the sentence is constructed, it sounds like the PR/commercial team are trying to hint that future phases are on the table.

Imagine 100ktpa for 70 years... with SMS recycling the lithium, perhaps with an additional CEZ relationship to recycle the raw materials. It almost sounds like an EU battery alliance utopia!!

Besides, the SCLP "COVID-vaccine" is probably just as far away as Valirx's COVID efforts (frankly, I do not understand the plausibility of either technology, both companies seem to have reasonably efficacious technologies in quite different oncology treatments).

From what I can see, Scancell have proposed to run a T-cell phase 1 trial "during 2021". OK, so T-cells have excellent potential, but it is slightly like taking a sledgehammer to an avocado. I would presume only terminally ill COVID patients would be treated with an expensive T-cell "vaccine"? Limiting the market somewhat.

Even if this treatment works, it would not plausibly be on the market before 2024, unless some seriously fast-track clinical trials are proposed (occasionally on terminally ill patients, you can leap over some hurdles, if they're dying in agony, it is harder to make things much worse). So really, it's a pipe-dream among 500 other COVID-related clinical trials.

It is fair to say, over the years there have been numerous "experts" who only post unquestionably loyal and rampy long posts on the SCLP board, who occasionally venture over to the VAL board to exclusively say negative things.

In the business world, it is a sad fact of AIM that most ridiculously pro rampers on each message board are usually the companies own PR/social media team, or some connection to their financial PR/broker/external media team pushing out propaganda. I mean, it is what they are paid to do. You can usually spot these by the ridiculously loyal postings that would be quite absurd for PIs to utter.

It was hilarious several years back, SCLP trolls were here in large numbers, so there was a retaliatory board-raid on the SCLP site for several days, spamming nothing but a negative slant on SCLP's technology. If nothing else, I found it amusing to notice that around the same time, SCLP brought in a new financial PR agent with expertise in "crisis management". Could be coincidence, but perhaps not!

Not directly involving EMH, but interesting as a background note on EU/Aussie Lithium Ion recycling plans:

August 3rd 2020: https://www.sms-group.com/press-media/press-releases/press-detail/neometals-and-sms-group-set-up-joint-venture-for-recycling-lithium-ion-batteries-1440/

"Neometals and SMS group set up 'Primobius', a 50:50 joint venture for the recycling of lithium batteries as well as the sustainable recovery of valuable constituents from end-of-life batteries
The objective is the commercialization of joint recycling technology for fast-growing volumes of end-of-life batteries
Primobius plans a demonstration plant in Germany based on the hub-and-spoke system"

It makes sense with SMS Group involved with Cinovec.

https://www.sms-group.com/br/press-media/press-releases/press-detail/sms-group-supplies-front-end-engineering-design-feed-for-europes-first-lithium-battery-chemicals-facility-1496/

Interesting comments here.

"Given the situation that in Europe lithium ion battery production capacities equating approx. 200 GWh per year are being planned or currently under construction and the fact that approx. 800 kilograms of lithium carbonate is needed to produce one GWh of battery capacity, the production volume planned by Geomet in the first phase of the project will only cover a small portion of the medium-term demand generated in Europe. This is the reason for SMS group to believe that there will be increasing lithium project activity right on the doorstep within Europe and this FEED contract appointment, at what is Europe’s largest hard-rock lithium resource, will put SMS group at the forefront of this developing industry."

First time I have seen a semi-official hint at phases beyond Phase 1 (22.5ktpa)!

Apologies Iain, I may have mis-interpreted the text.

Is the text relating to 30th April 2020 & 16th June 2020, relating to extensions to Cinovec North-West & Cinovec East, are these time extensions? Or future drilling resource extensions?

Will be interesting to see how Suzy wants to play this. She seems to have indicated to the market the next step is a JV/partnership, would be slightly suicidal to back away from that move (indeed, it seems obvious that certain trolls were very unhappy at Satu's "go it alone" strategy).

Heck, even if it is only £50-75m (they have spent £25m on trials, it seems ballpark conservative valuation), that is still multiples of today's MCAP.

Interesting quotes abound in the RNS annual accounts

"Cinovec project fully funded to the decision to construct, paving the way for Cinovec to become the first European Union producer of battery grade lithium compounds from a local lithium resource."

Was hoping to see confirmation of Prague listing, but appreciate the annual accounts are tricky enough to complete.

Once on Prague exchange, local govt will shower EMH with positive news, as their buddies buy in and they start drooling over future tax revenues.

Interesting they keep mentioning additional exploration, are they likely to expand on the known 7 million tonnes of Lithium? Doesn't look like a huge expansion, but perhaps 8mt? (8,000,000 tonnes x $8000 per tonne is an incredible valuation...).

Ha, I sold at 53p and bought back in at 28p. For once I actually timed this pretty well.

Looks strong this morning, touching 33.5 to 34p.

You can buy shares on the 'open' stock market. Or you can trade them privately and separately 'off book', but with these type of trades, you will need to notify the exchange manually. Sometimes they call these 'over the counter OTC' trades.

This can just mean two individuals or companies shared them directly via contract, but to be honest, it is seen as being open to 'concealment' of true intent.

Short term traders out, quite a lot of interest showing again this morning?

Perhaps the spike took out the orders and a modest slow upward trend has recovered. A good sign of background demand

Vicjain, technically nothing has changed, it's a natural drop after a ludicrous 14x spike up.

It will likely oversell; the market will become positive again, sentiment will rise and the SP will return.

Yeah, I like to think I was originally a LTH, but I have learned Valirx newsflow is quite predictable and far more profitable to trade in and out.

My own stupid fault really. I got greedy and didn't book ridiculous gains when the 401 RNS landed, since then, I trade on the sentiment and newsflow only, up or down.

I might buy back in heavy late November, depending on how the equity and JV newsflow bubbles along.

Good buying point at 20p..?

Has legs for December.

Hm that is an unfortunate trend. 36p?

On the positive side, apparently these patients typically have a less than 50% chance of living 2 years, so I am curious & pleased to see there were no deaths reported.

I suppose the questions are:

--Are they going to try more regular dosing (perhaps an early 2 weeks of daily dosing, followed by weekly)
--No PSA/metastatic data?
--Do they want to perform more trials by themselves?
--Are they going to partner up? If it will need more regular dosing at say 4/8mg, that will be another year of phase 1 tolerability?
--If they are going to partner up and hit a 2b-3 trial? Or just accept the results how they are today, progress with additional trials, with perhaps further daily dosing run in the background as a separate trial